Literature DB >> 16459153

Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC.

Katsuhiro Ono1, Sadahiro Kamiya, Takuhiko Akatsu, Chika Nakamura, Minqi Li, Norio Amizuka, Kunio Matsumoto, Toshikazu Nakamura, Nobuo Kugai, Seiki Wada.   

Abstract

Some cancers frequently affect the skeleton, and the bone microenvironment supports growth of certain cancer cells. After tumors metastasize to bone, they stimulate osteoclastogenesis and expand in the bone tissue. Hepatocyte growth factor (HGF), which was originally identified as a potent mitogen for hepatocytes, promotes tumor growth, invasion and metastasis. HGF is mainly produced by cells of mesenchymal origin, and osteoblasts/osteocytes and bone marrow stromal cells originate from mesenchymal cells. However, it is not clear what effect HGF has on tumor progression in bone metastasis. In the present study, we investigated the roles of HGF in bone metastasis using the mouse mammary cancer cell line BALB/c-MC. Cancer cells injected into hearts of mice metastasized to bone in their hind limbs. HGF immunoreactivity was detected in the stroma surrounding the tumor nests, and blood vessels expressing CD31 (a marker of endothelial cells) were observed in the HGF-positive area. To identify the cells producing HGF, we measured concentration of HGF in culture media. HGF concentration was elevated in osteoblast cultures (3.13+/-0.25 ng/ml), whereas HGF was undetectable (<0.4 ng/ml) in BALB/c-MC and bone marrow cell cultures. HGF concentration in osteoblast cultures increased 2.5-fold in response to 10(-6) M PGE(2). Addition of HGF to BALB/c-MC cultures caused doubling of the cell number. Moreover, Western blot analysis revealed expression of c-Met/HGF receptor by BALB/c-MC. In the Matrigel invasion chamber assay, addition of HGF to the bottom well increased the rate at which BALB/c-MC invaded the bottom well through the membrane. Furthermore, when osteoblasts were cultured in the bottom well, the number of BALB/c-MC cells that invaded the bottom well through the membrane increased 3.7-fold, compared to assays without osteoblasts. Addition of NK4, an inhibitor of HGF, completely abolished the enhancement of the invasive potential of the BALB/c-MC cells in the presence of osteoblasts. These findings suggest that HGF produced by osteoblasts induces migration of cancer cells from sinusoidal capillaries to bone marrow space and stimulates growth of cancer cells in the bone microenvironment. Thus, osteoblasts appear to promote bone metastasis of some cancers via HGF-c-Met signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16459153     DOI: 10.1016/j.bone.2005.12.006

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  14 in total

1.  Cabozantinib as a novel therapy for renal cell carcinoma.

Authors:  Ulka Vaishampayan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

2.  Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Authors:  David C Smith; Matthew R Smith; Christopher Sweeney; Aymen A Elfiky; Christopher Logothetis; Paul G Corn; Nicholas J Vogelzang; Eric J Small; Andrea L Harzstark; Michael S Gordon; Ulka N Vaishampayan; Naomi B Haas; Alexander I Spira; Primo N Lara; Chia-Chi Lin; Sandy Srinivas; Avishay Sella; Patrick Schöffski; Christian Scheffold; Aaron L Weitzman; Maha Hussain
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

3.  Human Cell Surface Receptors as Molecular Imaging Candidates for Metastatic Prostate Cancer.

Authors:  Isis C Sroka; Gerald D Pond; Raymond B Nagle; Frank Porreca; Tamara King; Gary Pestano; Bernard W Futscher; Jaime M Gard; Janice Riley; Anne E Cress
Journal:  Open Prost Cancer J       Date:  2009-01-01

Review 4.  MET and VEGF: synergistic targets in castration-resistant prostate cancer.

Authors:  D T Aftab; D M McDonald
Journal:  Clin Transl Oncol       Date:  2011-10       Impact factor: 3.405

Review 5.  Metastasis: a therapeutic target for cancer.

Authors:  Patricia S Steeg; Dan Theodorescu
Journal:  Nat Clin Pract Oncol       Date:  2008-02-05

Review 6.  Development of cabozantinib for the treatment of prostate cancer.

Authors:  Ulka N Vaishampayan
Journal:  Core Evid       Date:  2014-04-23

7.  MET expression during prostate cancer progression.

Authors:  Esther I Verhoef; Kimberley Kolijn; Maria J De Herdt; Berdine van der Steen; A Marije Hoogland; Hein F B M Sleddens; Leendert H J Looijenga; Geert J L H van Leenders
Journal:  Oncotarget       Date:  2016-05-24

Review 8.  Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection.

Authors:  Steven S Yu; David I Quinn; Tanya B Dorff
Journal:  Onco Targets Ther       Date:  2016-09-23       Impact factor: 4.147

9.  High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.

Authors:  Hidenori Fujita; Akira Gomori; Yayoi Fujioka; Yuki Kataoka; Kenji Tanaka; Akihiro Hashimoto; Takamasa Suzuki; Kenjiro Ito; Tomonori Haruma; Hiromi Yamamoto-Yokoi; Naomoto Harada; Motomu Sakuragi; Nobuyuki Oda; Kenichi Matsuo; Masaki Inada; Kazuhiko Yonekura
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

10.  Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway.

Authors:  Sonia Vallet; Muhammad Hasan Bashari; Feng-Juan Fan; Stefano Malvestiti; Andreas Schneeweiss; Patrick Wuchter; Dirk Jäger; Klaus Podar
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.